RxDoctor Payments Data

Nadakavil Koshy, MD

Cardiovascular Disease · Sarasota, FLNPI 1841282076

Payments from drug & device makers

$21,347in general payments, 2019–2025

Across 139 payments — averaging $153.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$14K
  • Histosonics, Inc.$4K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$606
  • Astellas Pharma US Inc$438
  • Pfizer$419
  • Novartis$417
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$3,94951%
  • Food & beverage$3,55746%
  • Education$2383%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,347 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$268,200
Medicare patients
3,579
Services billed
6,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban270$278,991
CamzyosMavacamten19$152,634
XareltoRivaroxaban53$67,541
EntrestoSacubitril/Valsartan33$33,689
JardianceEmpagliflozin11$16,272
FarxigaDapagliflozin Propanediol26$15,102
BrilintaTicagrelor28$13,717
Metoprolol Succinate197$2,393
Valsartan47$1,916
Propafenone Hcl21$1,715
Ezetimibe66$1,576
Digoxin38$1,387
Metoprolol Tartrate204$1,316
ClopidogrelClopidogrel Bisulfate96$1,273
SotalolSotalol Hcl51$1,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$419$278,991270 claims
E.r. Squibb & Sons, L.L.C.Camzyos$151$152,63419 claims
Johnson & JohnsonXarelto$151$67,54153 claims
NovartisEntresto$417$33,68933 claims
AstraZenecaFarxiga, Brilinta$62$28,81954 claims
Boehringer IngelheimJardiance$236$16,27211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →